Multicenter Clinical Evaluation of the (1->3) -D-Glucan Assay as an Aid to Diagnosis of Fungal Infections in Humans
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Measurement of (1-->3)-beta-D-Glucan (BG) has emerged as an adjunct diagnostic strategy for invasive fungal infections (IFI). METHODS: Subjects at 6 clinical sites in the United States were enrolled as either fungal infection-negative subjects (n = 170) or subjects with proven or probable IFI according to European Organization for the Research and Treatment of Cancer/Mycoses Study Group criteria (n = 163). A central laboratory and 4 sites performed assays. A single sample was obtained per patient and was evaluated using an assay to detect serum BG derived from fungal cell walls (range, 0 to > 7000 pg/mL). RESULTS: At a cutoff of 60 pg/mL, the sensitivity and specificity of the assay were 69.9% and 87.1%, respectively, with a positive predictive value (PPV) of 83.8% and a negative predictive value (NPV) of 75.1%. At a cutoff value of 80 pg/mL, the sensitivity and specificity were 64.4% and 92.4%, respectively, with a PPV of 89% and an NPV of 73%. Of the 107 patients with proven candidiasis, 81.3% had positive results at a cutoff value of 60 pg/mL, and 77.6% had positive results at a cutoff value of 80 pg/mL. Of the 10 patients with aspergillosis, 80% had positive results at cutoff values of 60 and 80 pg/mL. The 3 subjects diagnosed with Fusarium species had positive results at a cutoff value of 60 pg/mL. Patients infected with Mucor or Rhizopus species (both of which lack BG) had negative results at both cutoff values, and of the 12 patients with Cryptococcus infection, 3 had positive results at a cutoff value of 60 pg/mL, and 2 had positive results at a cutoff value of 80 pg/mL. Of the subjects with proven positive results who were receiving antifungal therapy (n = 118), 72.9% had results positive for BG at a cutoff value of 60 pg/mL, and 69.5% had results positive for BG at a cutoff value of 80 pg/mL. The interlaboratory sample test r2 was 0.93. CONCLUSION: Reproducible assay results with high specificity and high PPV in a multicenter setting demonstrate that use of an assay to detect serum BG derived from fungal cell walls is a useful diagnostic adjunct for IFI.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sensitivity and specificity have been estimated to be 69.9 and 87.1%, respectively [47], as there are a high number of false positive results.”
From Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis (2009) · cites this paper as [47]
In the citing paper
“(1 ?3)-b-D-glucan is a component of the cell wall of many fungi and has been proposed as a non-specific marker for invasive fungal infections.”
From Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis (2009) · cites this paper as [47]
In the citing paper
“b-1, 3-D-Glucan detection has also been evaluated in critically ill patients, with sensitivity and specificity for diagnosis of IC estimated to be 69.9% and 87.1%, respectively.63”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [63]
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331 · cited 3×
“Subjects. Subjects without IFI and subjects with proven or probable IFI (determined according to the European Organization for the Research and Treatment of Cancer/Mycoses Study Group [EORTC/MSG] criteria [ 15 ]) from 6 clinical sites in the United States consented to participate in this study, and a single blood samp…”
MethodSelf-citation(2012) · Hepatogastroenterology · doi:10.5754/hge11801 · Cited by 802
Odabasi, Z., Mattiuzzi, G., Estey, E., Kantarjian, H., Saeki, F., Ridge, R. J., Ketchum, P. A., Finkelman, M. A., Rex, J. H., & Ostrosky-Zeichner, L. (2004) · Clinical Infectious Diseases · doi:10.1086/421944 · Cited by 642 · cited 4×
“The reactivity of the Fungitell assay with Pachyman standard is lower than that of the Fungitec-G assay [9].”
BackgroundMethodSelf-citationObayashi, T., Kawai, T., Yoshida, M., Mori, T., Goto, H., Yasuoka, A., Shimada, K., Iwasaki, H., Teshima, H., Kohno, S., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91152-9 · Cited by 530
Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N., Kauffman, C. A., Cleary, J., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3149-3154.2003 · Cited by 498 · cited 1×
“parapsilosis [19].”
Self-citationThe use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis
Horvath, J. A., & Dummer, S. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)89455-7 · Cited by 323 · cited 1×
“of cases of invasive aspergillosis [4].”
The New Fungal Opportunists Are Coming
Perfect, J. R., & Schell, W. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s112 · Cited by 224 · cited 1×
“critical care [1].”
Miyazaki, T., Kohno, S., Mitsutake, K., Maesaki, S., Tanaka, K., Ishikawa, N., & Hara, K. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.12.3115-3118.1995 · Cited by 204
Digby, J., Kalbfleisch, J. H., Glenn, A., Larsen, A. R., Browder, W., & Williams, D. L. (2003) · Clinical and Vaccine Immunology · doi:10.1128/cdli.10.5.882-885.2003 · Cited by 153 · cited 2×
“[18] observed low specificity for fungal infections in a study involving 46 subjects in intensive care units.”
BackgroundMolecular mechanism of hemolymph clotting system in Limulus
Iwanaga, S., Miyata, T., Tokunaga, F., & Muta, T. (1992) · Thrombosis Research · doi:10.1016/0049-3848(92)90124-s · Cited by 133 · cited 1×
“BG produced by fungi [6] is detected by a glucan assay on the basis of its recognition by the innate immune system of horseshoe crabs, specifically Tachypleus tridentatus and Limulus polyphemus [7].”
Background
Research works printed but not linked: 1
- Nakao, 1997, Hepato-gastroenterology, 44, 1413
Cited by
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Self-citationFreifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
Self-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
“Detection of b-D-glucan has shown good overall performance characteristics, with a sensitivity of 80%–90% in patients with candidemia [104, 105], confirming previous results obtained in patients with hematological malignancies [106].”
ResultSelf-citationPatterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
“Aerosolized formulations of AmBmay be considered as prophylaxis in patients with prolonged neutropenia (patients receiving induction/reinduction therapy for acute leukemia and allogeneic HSCT recipients following conditioning or during treatment of graft-vs-host disease [GVHD]) and in lung transplant recipients (weak…”
MethodInfluentialSelf-citationWalsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
“assay was sensitive and specific in early detection of 20 proven or probable invasive fungal infections, including candidiasis, fusariosis, trichosporonosis, and aspergillosis [66, 69].”
Self-citationUllmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
The Fungal Cell Wall: Structure, Biosynthesis, and Function
Gow, N. A. R., Latge, J.-P., & Munro, C. A. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0035-2016 · Cited by 1,423
Kullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Fusarium Infections in Immunocompromised Patients
Nucci, M., & Anaissie, E. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00014-07 · Cited by 983
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., Lanternier, F., Pagano, L., Skiada, A., Akova, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12371 · Cited by 863
Emerging opportunistic yeast infections
Miceli, M. H., Díaz, J. A., & Lee, S. A. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70218-8 · Cited by 811
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq147 · Cited by 704
Self-citation-D-Glucan Assay for the Diagnosis of Invasive Fungal Infections: A Meta-analysis
Karageorgopoulos, D. E., Vouloumanou, E. K., Ntziora, F., Michalopoulos, A., Rafailidis, P. I., & Falagas, M. E. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq206 · Cited by 538
“The remaining 7 studies were not included in the meta-analysis, because they used healthy individuals as controls [34, 36, 40, 44, 45], included patients with possible IFIs as case patients [30], or provided data only for sample-based BDG analysis [42].”
BackgroundMethodInfluentialArendrup, M. C., Boekhout, T., Akova, M., Meis, J. F., Cornely, O. A., & Lortholary, O. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12360 · Cited by 529
Tortorano, A. M., Richardson, M., Roilides, E., van Diepeningen, A., Caira, M., Munoz, P., Johnson, E., Meletiadis, J., Pana, Z.-D., Lackner, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12465 · Cited by 523
Septic shock attributed to Candida infection: Importance of empiric therapy and source control.
Kollef, M., Micek, S., Hampton, N., Doherty, J. A., & Kumar, A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis305 · Cited by 477
“Preliminary studies of biomarkers and rapid microbiologic diagnostic techniques hold promise for earlier identification of Candida species as the etiology of septic shock [35, 36].”
Segal, B. H., Herbrecht, R., Stevens, D. A., Ostrosky‐Zeichner, L., Sobel, J., Viscoli, C., Walsh, T. J., Maertens, J., Patterson, T. F., Perfect, J. R., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590566 · Cited by 468
“Serum (1r3)-b-d-glucan can be a valuable diagnostic adjunct in a number of IFDs, including invasive candidiasis and aspergillosis [2, 44, 45].”
Self-citationClinical and laboratory update on blastomycosis.
Saccente, M., & Woods, G. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00056-09 · Cited by 450
Putative Role of β-1,3 Glucans in Candida albicans Biofilm Resistance
Nett, J., Lincoln, L., Marchillo, K., Massey, R., Holoyda, K., Hoff, B., VanHandel, M., & Andes, D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01056-06 · Cited by 407
The Era of Molecular and Other Non-Culture-Based Methods in Diagnosis of Sepsis
Mancini, N., Carletti, S., Ghidoli, N., Cichero, P., Burioni, R., & Clementi, M. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00043-09 · Cited by 407
León, C., Ruiz-Santana, S., Saavedra, P., Galván, B., Blanco, A., Castro, C., Balasini, C., Utande-Vázquez, A., González de Molina, F. J., Blasco-Navalproto, M. A., et al. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e31819daa14 · Cited by 375
“However, recently, early results of an assay to measure the serum (1–3)-beta-Dglucan, also derived from fungal cell walls, have been found to be a promising tool to diagnose invasive fungal infections, most of them being IC (34).”
BackgroundResultInfluentialPrevention and Treatment of Cancer-Related Infections
Baden, L. R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E. R., Freifeld, A. G., Garzon, R., Greene, J. N., Greer, J. P., Ito, J. I., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0146 · Cited by 368
Self-citationInvasive Aspergillosis: Epidemiology, Diagnosis and Management in Immunocompromised Patients
Maschmeyer, G., Haas, A., & Cornely, O. A. (2007) · Drugs · doi:10.2165/00003495-200767110-00004 · Cited by 366
Invasive aspergillosis in the intensive care unit
Meersseman, W., Lagrou, K., Maertens, J., & Wijngaerden, E. V. (2007) · Clinical Infectious Diseases · doi:10.1086/518852 · Cited by 366
Molecular and Nonmolecular Diagnostic Methods for Invasive Fungal Infections
Arvanitis, M., Anagnostou, T., Fuchs, B. B., Caliendo, A. M., & Mylonakis, E. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00091-13 · Cited by 353
Current Approaches to Diagnosis and Treatment of Invasive Aspergillosis
Segal, B. H., & Walsh, T. J. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200505-727so · Cited by 334
Onishi, A., Sugiyama, D., Kogata, Y., Saegusa, J., Sugimoto, T., Kawano, S., Morinobu, A., Nishimura, K., & Kumagai, S. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.05267-11 · Cited by 328
Child Mortality According to Maternal and Infant HIV Status in Zimbabwe
Marinda, E., Humphrey, J. H., Iliff, P. J., Mutasa, K., Nathoo, K. J., Piwoz, E. G., Moulton, L. H., Salama, P., & Ward, B. J. (2007) · Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000264527.69954.4c · Cited by 314
Lamoth, F., Cruciani, M., Mengoli, C., Castagnola, E., Lortholary, O., Richardson, M., Marchetti, O., & (ECIL-3), O. B. O. T. T. E. C. O. I. I. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir897 · Cited by 302
Marchetti, O., Lamoth, F., Mikulska, M., Viscoli, C., Verweij, P., Bretagne, S., & Groups, A. T. E. C. O. I. I. L. (. L. W. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.178 · Cited by 275
Vandewoude, K. H., Blot, S. I., Depuydt, P., Benoit, D., Temmerman, W., Colardyn, F., & Vogelaers, D. (2006) · Critical Care · doi:10.1186/cc4823 · Cited by 268
“Furthermore, prospective research should include non-culture methods for diagnosis, such as the detection of galactomannan, PCR, and beta-D-glucan in non-neutropenic patients [35,36].”
MethodSenn, L., Robinson, J. O., Schmidt, S., Knaup, M., Asahi, N., Satomura, S., Matsuura, S., Duvoisin, B., Bille, J., Calandra, T., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/527382 · Cited by 263
Invasive fungal infections in solid organ transplant recipients
Gavaldà, J., Meije, Y., Fortún, J., Roilides, E., Saliba, F., Lortholary, O., Muñoz, P., Grossi, P., & Cuenca-Estrella, M. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12660 · Cited by 232
Pappas, P. G. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.07.004 · Cited by 227
Self-citationMOFENSON, L. M., Brady, M. T., Danner, S. P., Dominguez, K. L., Hazra, R., Handelsman, E. L., Havens, P. L., Nesheim, S. R., Read, J. S., Serchuck, L. K., et al. (2009) · PubMed · Cited by 282
Diagnostic Performance of the (1→3)‐β‐ d ‐Glucan Assay for Invasive Fungal Disease
Koo, S., Bryar, J. M., Page, J. H., Baden, L. R., & Marty, F. M. (2009) · Clinical Infectious Diseases · doi:10.1086/647942 · Cited by 220
Bench-to-bedside review: Candida infections in the intensive care unit
Méan, M., Marchetti, O., & Calandra, T. (2008) · Critical Care · doi:10.1186/cc6212 · Cited by 217
Opportunistic invasive fungal infections: diagnosis & clinical management.
Badiee, P., & Hashemizadeh, Z. (2014) · PubMed Central · Cited by 331
Point-Counterpoint: β- d -Glucan Testing Is Important for Diagnosis of Invasive Fungal Infections
Theel, E. S., & Doern, C. D. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.01737-13 · Cited by 203
Aspergillosis: Spectrum of Disease, Diagnosis, and Treatment
Barnes, P. D., & Marr, K. A. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.06.001 · Cited by 205
β-Glucan Antigenemia Anticipates Diagnosis of Blood Culture–Negative Intraabdominal Candidiasis
Tissot, F., Lamoth, F., Hauser, P. M., Orasch, C., Flückiger, U., Siegemund, M., Zimmerli, S., Calandra, T., Bille, J., Eggimann, P., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201211-2069oc · Cited by 203
Bassetti, M., Marchetti, M., Chakrabarti, A., Colizza, S., Garnacho-Montero, J., Kett, D. H., Munoz, P., Cristini, F., Andoniadou, A., Viale, P., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-013-3109-3 · Cited by 198
Self-citationWhite, P. L., Wingard, J. R., Bretagne, S., Löffler, J., Patterson, T. F., Slavin, M. A., Barnes, R. A., Pappas, P. G., & Donnelly, J. P. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ507 · Cited by 193
Self-citationHachem, R. Y., Kontoyiannis, D. P., Chemaly, R. F., Jiang, Y., Reitzel, R., & Raad, I. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00506-08 · Cited by 184
“Similarly, variable results have been reported for BG assay, with a slightly higher sensitivity and specificity, ranging from 70% to 90% (14, 23 ).”
BackgroundResultInfluentialObayashi, T., Negishi, K., Suzuki, T., & Funata, N. (2008) · Clinical Infectious Diseases · doi:10.1086/588295 · Cited by 183
“The clinical usefulness of the b-glucan assay was also documented outside of Japan [4, 5 ], and the test was recently approved by the US Food and Drug Administration (FDA), although the test kit that the FDA used (Fungitell; Associates of Cape Cod) is different than the test evaluated here with respect to its reactivi…”
BackgroundMethodResultInfluentialPosteraro, B., De Pascale, G., Tumbarello, M., Torelli, R., Pennisi, M. A., Bello, G., Maviglia, R., Fadda, G., Sanguinetti, M., & Antonelli, M. (2011) · Critical Care · doi:10.1186/cc10507 · Cited by 185
“[35], the sensitivity of the assay for patients with proven IC (n = 107; cut-off, 80 pg/mL) was 77.”
BackgroundMethodResultConsensus guidelines for the diagnosis and management of invasive aspergillosis, 2021
Douglas, A. P., Smibert, O. C., Bajel, A., Halliday, C. L., Lavee, O., McMullan, B., Yong, M. K., van Hal, S. J., Chen, S. C. ‐., & the Australasian Antifungal Guidelines Steering Committee (2021) · Internal Medicine Journal · doi:10.1111/imj.15591 · Cited by 179
Invasive Mycoses: Diagnostic Challenges
Ostrosky-Zeichner, L. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.10.008 · Cited by 176
Self-citationEpidemiology and treatment approaches in management of invasive fungal infections
Ito, J. I., Kriengkauykiat, Dadwal, S., & Kriengkauykiat (2011) · Clinical Epidemiology · doi:10.2147/clep.s12502 · Cited by 203
“90% in invasive candidiasis.(78,79) It can also be positive in a number of other invasive fungal infections (such as aspergillosis and fusariosis).”
BackgroundInvasive Fungal Infections in the ICU: How to Approach, How to Treat
Paramythiotou, E., Frantzeskaki, F., Flevari, A., Armaganidis, A., & Dimopoulos, G. (2014) · Molecules · doi:10.3390/molecules19011085 · Cited by 175
“The detection of 1,3-β-D-glucan (BG) (Fungitell Assay; Cape Cod, MA, USA), which is a pan-fungal marker (except for Mucorales and Cryptococcus), demonstrates variable sensitivity depending on the cut-off diagnostic value and the Candida species under consideration [40,41,44].”
BackgroundGuery, B. P., Arendrup, M. C., Auzinger, G., Azoulay, É., Borges Sá, M., Johnson, E. M., Müller, E., Putensen, C., Rotstein, C., Sganga, G., et al. (2009) · Intensive Care Medicine · doi:10.1007/s00134-008-1338-7 · Cited by 173
“1%, respectively [47], as there are a high number of false positive results.”
BackgroundContribution of the (1→3)-β- d -Glucan Assay for Diagnosis of Invasive Fungal Infections
Persat, F., Ranque, S., Derouin, F., Michel-Nguyen, A., Picot, S., & Sulahian, A. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.02091-07 · Cited by 173
Emerging and reemerging fungal infections
Lockhart, S. R., & Guarner, J. (2019) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2019.04.010 · Cited by 169
Steinbrink, J. M., & Miceli, M. H. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.009 · Cited by 166
Segal, B. H., Almyroudis, N. G., Battiwalla, M., Herbrecht, R., Perfect, J. R., Walsh, T. J., & Wingard, J. R. (2007) · Clinical Infectious Diseases · doi:10.1086/510677 · Cited by 168
“with use of the b-glucan assay in HSCT recipients is limited [70], and the use of”
MethodSelf-citationCurrent challenges in the management of invasive fungal infections
Lai, C.-C., Tan, C.-K., Huang, Y.-T., Shao, P.-L., & Hsueh, P.-R. (2008) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-007-0595-7 · Cited by 165
“, but not for zygomycetes and Cryptococcus, which contain little or no BDG.(63) The sensitivity and specifi city of the BDG assay were 69.”
BackgroundInfluentialAslam, S., Rotstein, C., & Practice, T. A. I. D. C. O. (2019) · Clinical Transplantation · doi:10.1111/ctr.13623 · Cited by 160
Advances in pathogenesis and management of sepsis
Cinel, I., & Dellinger, R. P. (2007) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32818be70a · Cited by 160
Barnes, P. D., & Marr, K. A. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06812.x · Cited by 172
“Early studies evaluating the test that is marketed in the United States suggest a sensitivity and specificity of 62% and 94% respectively, for diagnosing IFIs (Ostrosky-Zeichner et al, 2005).”
BackgroundContemporary tools for the diagnosis and management of invasive mycoses
Alexander, B. D., & Pfaller, M. A. (2006) · Clinical Infectious Diseases · doi:10.1086/504491 · Cited by 147
“Laboratory Tools for Invasive Mycoses • CID 2006:43 (Suppl 1) • S21 patients with IFIs and healthy control subjects [35] and for the early diagnosis of IFIs in patients with hematologic malignancies [34, 36].”
BackgroundSelf-citationMaschmeyer, G., Carratalà, J., Buchheidt, D., Hamprecht, A. G., Heußel, C. P., Kahl, C., Lorenz, J., Neumann, S., Rieger, C. T., Ruhnke, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu192 · Cited by 151
“Details on antigen testing for fungal infection, including those other than aspergillosis [93], have been reviewed in a separate evidence-based guideline of our group [94].”
BackgroundManagement of invasive pulmonary aspergillosis in non-neutropenic critically ill patients
Trof, R. J., Beishuizen, A., Debets-Ossenkopp, Y. J., Girbes, A. R. J., & Groeneveld, A. B. J. (2007) · Intensive Care Medicine · doi:10.1007/s00134-007-0791-z · Cited by 145
He, S., Hang, J.-P., Zhang, L., Wang, F., Zhang, D., & Gong, F.-H. (2014) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2014.06.009 · Cited by 158
Role of (1→3)-β-D-glucan in the diagnosis of invasive aspergillosis
Marty, F. M., & Koo, S. (2008) · Medical Mycology · doi:10.1080/13693780802308454 · Cited by 137
Ruhnke, M., Rickerts, V., Cornely, O. A., Buchheidt, D., Glöckner, A., Heinz, W., Höhl, R., Horré, R., Karthaus, M., Kujath, P., et al. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02040.x · Cited by 148
(1,3)- -D-Glucan as a Prognostic Marker of Treatment Response in Invasive Candidiasis
Jaijakul, S., Vázquez, J. A., Swanson, R. N., & Ostrosky-Zeichner, L. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis456 · Cited by 149
Self-citationPneumocystis jirovecii pneumonia in non-HIV-infected patients
Reid, A., Chen, S. C. ‐., & Worth, L. J. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32834cac17 · Cited by 133
Alam, F. F., Mustafa, A. S., & Khan, Z. U. (2007) · BMC Infectious Diseases · doi:10.1186/1471-2334-7-103 · Cited by 154
Martino, R., Parody, R., Fukuda, T., Maertens, J., Theunissen, K., Ho, A. Y. L., Mufti, G. J., Kröger, N. M., Zander, A., Heim, D. A., et al. (2006) · Blood · doi:10.1182/blood-2006-03-008706 · Cited by 131
Ellis, M. E., al-Ramadi, B. K., Finkelman, M., Hedström, U., Kristensen, J., Alizadeh, H., & Klingspor, L. (2008) · Journal of Medical Microbiology · doi:10.1099/jmm.0.47479-0 · Cited by 134
“Finally it is known that the assay can be affected by certain biologics such as immunoglobulins, platelets and gauze (Associates of Cape Cod, 2004; Ostrosky-Zeichner et al., 2005).”
BackgroundInfluentialSelf-citationDetection and investigation of invasive mould disease
Cuenca‐Estrella, M., Bassetti, M., Lass‐Flörl, C., Racil, Z., Richardson, M. D., & Rogers, T. R. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq438 · Cited by 143
Effect of antifungal therapy timing on mortality in cancer patients with candidemia
Taur, Y., Cohen, N., Dubnow, S., Paskovaty, A., & Seo, S. K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00945-09 · Cited by 127
“Although it detects several types of fungi and is not specific to Candida, the beta-D-glucan (Fungitell) assay can also be useful in the early diagnosis of disease due to Candida (30).”
BackgroundFungal infections diagnosis – Past, present and future
Mendonça, A., Santos, H., Franco‐Duarte, R., & Sampaio, P. (2021) · Research in Microbiology · doi:10.1016/j.resmic.2021.103915 · Cited by 144
Maschmeyer, G., Beinert, T., Buchheidt, D., Cornely, O. A., Einsele, H., Heinz, W., Heußel, C. P., Kahl, C., Kiehl, M. G., Lorenz, J., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.05.001 · Cited by 125
Sulahian, A., Porcher, R., Bergeron, A., Touratier, S., Raffoux, E., Ménotti, J., Derouin, F., & Ribaud, P. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.03567-13 · Cited by 141
Sequencing and Analysis of Fungal rRNA Operons for Development of Broad-Range Fungal PCR Assays
Khot, P. D., Ko, D. L., & Fredricks, D. N. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.02383-08 · Cited by 123
Hanson, K. E., Pfeiffer, C. D., Lease, E. D., Balch, A. H., Zaas, A. K., Perfect, J. R., & Alexander, B. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042282 · Cited by 127
“To improve sensitivity as a screening test, a positive BDG cut-off of 60 pg/ml was selected based on the observation that 81% of IC patients will have a positive test at this level [15].”
MethodSelf-citationLaboratory Diagnosis of Invasive Aspergillosis: From Diagnosis to Prediction of Outcome
Barton, R. (2013) · Scientifica · doi:10.1155/2013/459405 · Cited by 138
“However, in the recent US PATH registry update culture of Aspergillus for the diagnosis of IA was still the most frequent laboratory approach [369].”
BackgroundAlexander, B. D., Smith, P. B., Davis, R. D., Perfect, J. R., & Reller, L. B. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01183-10 · Cited by 115
Self-citationRáčil, Z., Kocmanová, I., Lengerová, M., Weinbergerová, B., Burešová, L., Tošková, M., Winterová, J., Timilsina, S., Rodríguez, I. E., & Mayer, J. (2010) · Journal of Medical Microbiology · doi:10.1099/jmm.0.019299-0 · Cited by 117
1,3-β-D-Glucan in Patients Receiving Intravenous Amoxicillin–Clavulanic Acid
Mennink‐Kersten, M. A. S. H., Warris, A., & Verweij, P. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmc053340 · Cited by 114
Mohr, J., Sims, C. R., Paetznick, V. L., Rodríguez, J. E., Finkelman, M., Rex, J. H., & Ostrosky-Zeichner, L. L. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01240-10 · Cited by 124
“(19) in the critical care setting and are in general agreement with large recent surveys of BG in other patient populations and autopsy studies (4, 10, 13, 16, 17, 19).”
ResultSelf-citationSiberry, G. K., Abzug, M. J., Nachman, S., Brady, M. T., Dominguez, K. L., Handelsman, E. L., MOFENSON, L. M., Nesheim, S. R., Health, N. I. O., Prevention, C. F. D. C. A., et al. (2013) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000437856.09540.11 · Cited by 119
Blood (1->3)- -D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia
Sax, P. E., Komarow, L., Finkelman, M., Grant, P., Andersen, J., Scully, E. P., Powderly, W. G., & Zolopa, A. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir335 · Cited by 110
Self-citationNew insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis
Rammaert, B., Desjardins, A., & Lortholary, O. (2012) · Mycoses · doi:10.1111/j.1439-0507.2012.02182.x · Cited by 118
Early diagnosis of fungal infection in immunocompromised patients
Barnes, R. A. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm424 · Cited by 108
“Few data are available for the utility of b-D-glucan testing but this too may have value in identifying early infection and appears highly sensitive.(21) Experience in high-risk populations remains limited.”
BackgroundCandida Infections in Solid Organ Transplantation
Silveira, F. P., & Kusne, S. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12114 · Cited by 106
Emerging infections caused by non- Aspergillus filamentous fungi
Douglas, A. P., Chen, S. C.-A., & Slavin, M. A. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.01.011 · Cited by 116
Fungal diagnosis: how do we do it and can we do better?
Perfect, J. R. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.761134 · Cited by 120
Fungal Infections of the CNS: Treatment Strategies for the Immunocompromised Patient
Black, K. E., & Baden, L. R. (2007) · CNS Drugs · doi:10.2165/00023210-200721040-00004 · Cited by 115
“[51] Cellulose membranes used with some after full resolution of all signs and symptoms of the haemodialysis machines and in gauze may elevate disease.”
BackgroundCandida in Solid Organ Transplant Recipients
Pappas, P. G., & Silveira, F. P. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02909.x · Cited by 105
Self-citationSmith, P. B., Benjamin, D. K., Alexander, B. D., Johnson, M. D., Finkelman, M., & Steinbach, W. J. (2007) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00025-07 · Cited by 104
“The quantification of -glucan levels in uninfected and infected adult patients has been performed (10).”
BackgroundMethodSelf-citationTreatment of invasive candidiasis in the elderly: a review
Dimοpoulos, G., Flevari, A., Θεοδωρακοπούλου, Μ., VELEGRAKI, & Armaganidis (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s39120 · Cited by 131
Bhatti, Z., Shaukat, A., Almyroudis, N. G., & Segal, B. H. (2006) · Mycopathologia · doi:10.1007/s11046-006-0025-x · Cited by 111
Emerging moulds: epidemiological trends and antifungal resistance
Miceli, M. H., & Lee, S. A. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02032.x · Cited by 104
Early treatment of candidemia in adults: a review
Ostrosky-Zeichner, L., Kullberg, B. J., Bow, E. J., Hadley, S., León, C., Nucci, M., Patterson, T. F., & Perfect, J. R. (2011) · Medical Mycology · doi:10.3109/13693786.2010.512300 · Cited by 97
Self-citationJouault, T., Sarazin, A., Martinez‐Esparza, M., Fradin, C., Sendid, B., & Poulain, D. (2009) · Cellular Microbiology · doi:10.1111/j.1462-5822.2009.01318.x · Cited by 122
Trends in invasive fungal infections, with emphasis on invasive aspergillosis
Erjavec, Z., Kluin‐Nelemans, H. C., & Verweij, P. E. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02929.x · Cited by 95
“experience with BG detection in patients with invasive fungal infection is still limited, a possible role in the management of patients at risk of invasive Candida infection in the intensive care unit is currently being investigated [26].”
BackgroundGarnacho‐Montero, J., Olaechea, P., Álvarez-Lerma, F., Álvarez-Rocha, L., Blanquer, J., Galván, B., Rodríguez, A. H., Zaragoza, R., Aguado, J. M., Mensa, J., et al. (2013) · PubMed · Cited by 98
Metadata
- Authors
- Ostrosky-Zeichner, L., Alexander, B. D., Kett, D. H., Vazquez, J., Pappas, P. G., Saeki, F., Ketchum, P. A., Wingard, J., Schiff, R., Tamura, H., Finkelman, M. A., & Rex, J. H.
- Affiliations
- Duke University (US)
- University of Miami (US)
- University of Alabama at Birmingham (US)
- Seikagaku Corporation (Japan) (JP)
- University of Florida Health (US)
- College of Idaho (US)
- AstraZeneca (United Kingdom) (GB)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-09-01
- Volume
- 41
- Issue
- 5
- Pages
- 654-659
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2127508258
- Cited by
- 669
- References
- 26
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 12 · 2023: 14 · 2022: 7 · 2021: 15 · 2020: 16 · 2019: 25 · 2018: 25 · 2017: 21 · 2016: 38 · 2015: 29 · 2014: 50 · 2013: 42 · 2012: 39
- FWCI
- 29.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- β-1,3-glucan, invasive fungal infections, fungal infection diagnosis, candidiasis, aspergillosis, Fusarium, Mucor, Rhizopus, Cryptococcus, antifungal therapy, sensitivity and specificity, cut-off values, interlaboratory agreement, serum biomarkers, EORTC/MSG criteria
- MeSH terms
- Adult, Aged, Female, Humans, Male, Middle Aged, Mycoses, Proteoglycans, Sensitivity and Specificity, Reproducibility of Results, beta-Glucans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.